ArticleMolecular neurobiology2025
Causal Relationship Between Galectins With Neuroblastoma: A Mendelian Randomization Study.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Galectins are a family of proteins that are involved in various aspects of cancer, including tumor growth, cell migration, invasion, and metastasis. Galectins are subdivided into three families: prototype (such as Gal-1), chimera type (such as Gal-3), and tandem repeat type (such as Gal-9). Despite the evidence linking galectins to the risk of neuroblastoma (NB), the causal association between galectins and NB remains unclear. The primary objective of this study is to clarify the causal effect of galectins (including Gal-1, Gal-3, and Gal-9) on NB risk through a two-sample Mendelian randomization (MR) study. The MR study was performed using summary statistics from extensive genome-wide association studies. Single-nucleotide polymorphisms (SNPs) related to the exposure variables were used as instrumental variables. The primary outcome was NB risk, and the exposure variables included Gal-1, Gal-3, and Gal-9. We chose inverse-variance weighted (IVW), constrained maximum likelihood and model averaging (cML-MA), MR-robust adjusted profile score (MR-RAPS), simple mode, weighted median, and weighted mode as the statistical methods to assess the causal effect; and the IVW method was the primary statistical method. Odds ratio (OR) and 95% confidence interval (CI) were used as the evaluation indices for causality. According to the IVW with fixed-effect results, genetically predicted Gal-9 was associated with an increased risk of NB (OR = 1.639, 95% CI 1.171-2.293, P = 0.004). Similar risk estimates were obtained using cML-MA, MR-RAPS, simple mode, weighted median, and weighted mode. Additionally, the IVW with fixed-effect revealed there was no statistically significant association between Gal-1 and NB (P = 0.605), or between Gal-3 and NB (P = 0.258). No evidence of reverse causality was observed in the MR Steiger test. The results of the leave-one-out sensitivity test confirmed the stability and reliability of the causal effect estimates. This study identified a possible causal association between Gal-9 levels and the risk of NB through a two-sample MR analysis, which might provide preliminary yet insightful findings into the role of Gal-9 in the development of NB. We hope that our findings would promote the exploration of therapeutic strategies for NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.